vTv Therapeutics Inc.
VTVT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | -29.4% |
| R&D Expenses | $7 | $4 | $3 | $2 |
| G&A Expenses | $4 | $4 | $4 | $3 |
| SG&A Expenses | $4 | $4 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $11 | $8 | $7 | $5 |
| Operating Income | -$11 | -$8 | -$7 | -$5 |
| % Margin | – | – | – | -28,776.5% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$10 | -$7 | -$6 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$6 | -$5 | -$4 |
| % Margin | – | – | – | -21,376.5% |
| EPS | -1.08 | -0.92 | -0.77 | -0.63 |
| % Growth | -17.4% | -19.5% | -22.2% | – |
| EPS Diluted | -1.08 | -0.92 | -0.77 | -0.63 |
| Weighted Avg Shares Out | 8 | 7 | 7 | 6 |
| Weighted Avg Shares Out Dil | 8 | 7 | 7 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$8 | -$6 | -$4 |
| % Margin | – | – | – | -25,970.6% |